Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nymox Pharmaceutical will start patient recruitment in a small open-label short-term safety NX02-0020 trial of benign prostatic hyperplasia (BPH) drug NX-1207.
Subscribe to our email newsletter
NX-1207 is a novel patented drug developed by Nymox which is currently in Phase 3 trials
Th company intends to recruit around 100-200 patients who have already participated in previous studies of NX-1207.
In the trial, the company will evaluate the safety of repeat injection of the drug.
Nymox CEO Paul Averback said they are optimistic that the pivotal studies NX02-0017 and NX02-0018 will have full enrollment at a reasonable date.
"The 2 pivotal Phase 3 US studies passed the 500 patient enrollment milestone several months ago,"Averback said.
"We continue to negotiate and have discussions with a number of large marketing partners who have interest in licensing NX-1207 for the US and for Asia."
Nymox and Recordati entered into a development and commercialization licensing agreement of NX-1207 in Europe in December 2010.